Tioconazole

• CAT Number: A000357
• CAS Number: 65899-73-2
• Molecular Formula: C16H13Cl3N2OS
• Molecular Weight: 387.71
• Purity: ≥95%
• Synonyms: 65899-73-2; Trosyl; Vagistat-1; Tioconazolum; Vagistat
• Target: Fungal
• Storage: -20°C
• IUPAC Name: 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
• InChI: InChI=1S/C16H13Cl3N2OS/c17-12-1-2-13(14(18)7-12)15(8-21-5-4-20-10-21)22-9-11-3-6-23-16(11)19/h1-7,10,15H,8-9H2
• InChIKey: QXHHHPZILQDDPS-UHFFFAOYSA-N
• SMILES: C1=CC(=C(C=C1Cl)Cl)C(CN2C=CN=C2)OCC3=C(SC=C3)Cl

Tioconazole（Cat No.:A000357）is an antifungal agent commonly used for the treatment of vaginal yeast infections. It works by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes, leading to the disruption of cell membrane integrity and ultimately the death of the fungal cells. With a broad spectrum of activity against various Candida species, Tioconazole is often available in topical formulations such as creams, ointments, and suppositories. Its efficacy and minimal systemic absorption make it a preferred choice for localized treatment in fungal infections.

Reference

1: Ribeiro RF, Motta MH, Härter APG, Flores FC, Beck RCR, Schaffazick SR, de Bona
da Silva C. Spray-dried powders improve the controlled release of antifungal
tioconazole-loaded polymeric nanocapsules compared to with lyophilized products.
Mater Sci Eng C Mater Biol Appl. 2016 Feb;59:875-884. doi:
10.1016/j.msec.2015.10.035. Epub 2015 Oct 23. PubMed PMID: 26652443.

2: Rosato A, Piarulli M, Schiavone BI, Montagna MT, Caggiano G, Muraglia M,
Carone A, Franchini C, Corbo F. In vitro synergy testing of anidulafungin with
fluconazole, tioconazole, 5-flucytosine and amphotericin B against some Candida
spp. Med Chem. 2012 Jul;8(4):690-8. PubMed PMID: 22530916.

3: Grudzień M, Gajewska A, Pluciński F, Mazurek AP. Molecular properties relevant
to bioavailability of tioconazole and its derivatives. Acta Pol Pharm. 2008
Nov-Dec;65(6):757-8. PubMed PMID: 19172861.

4: Grudzień M, Krakowiak N, Pluciński F, Mazurek AP. Molecular properties of
oxyconazole and tioconazole as the criteria for their bioavailability estimation.
Acta Pol Pharm. 2008 Jan-Feb;65(1):123-4. PubMed PMID: 18536184.

5: Sidou F, Soto P. A randomized comparison of nail surface remanence of three
nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in
healthy volunteers. Int J Tissue React. 2004;26(1-2):17-24. Erratum in: Int J
Tissue React. 2004;26(3-4):119. PubMed PMID: 15573688.

6: Sobue S, Sekiguchi K. Difference in percutaneous absorption and intracutaneous
distribution in guinea pigs among topical antifungal drugs (tioconazole solution,
tioconazole cream, miconazole nitrate solution and bifonazole solution). Biol
Pharm Bull. 2004 Sep;27(9):1428-32. PubMed PMID: 15340231.

7: Simonetti G, Simonetti N, Villa A. Increase of activity of tioconazole against
resistant microorganisms by the addition of butylated hydroxyanisole. Int J
Antimicrob Agents. 2003 Oct;22(4):439-43. PubMed PMID: 14522107.

8: Pereira M, Fachin AL, Martinez-Rossi NM. The gene that determines resistance
to tioconazole and to acridine derivatives in Aspergillus nidulans may have a
corresponding gene in Trichophyton rubrum. Mycopathologia. 1998;143(2):71-5.
PubMed PMID: 10205888.

9: Faria A, Gonçalo S, Gonçalo M, Freitas C, Baptista PP. Allergic contact
dermatitis from tioconazole. Contact Dermatitis. 1996 Oct;35(4):250-2. PubMed
PMID: 8957651.

10: Heikkilä H, Stubb S, Reitamo S. A study of 72 patients with contact allergy
to tioconazole. Br J Dermatol. 1996 Apr;134(4):678-80. PubMed PMID: 8733370.